Vaishali Pharma (VAISHALI) Q2 FY27 Profit Soars 73% Despite a 10% Revenue Drop
Vaishali Pharma's Q2 FY27 net profit surged 73% year-on-year to ₹2.06 crore, driven by a sharp contraction in total expenses, even as revenue declined by 9.8%.
Vaishali Pharma posted a strong profit of ₹2.06 crore in Q2 FY27, up 73% from last year. The growth came from disciplined cost control, which offset a nearly 10% drop in revenue from operations.
For a pharmaceutical trading company, the quarter is often a story of volume and margin. Vaishali Pharma’s latest results tell a different tale, where profitability surged not on sales growth but on a disciplined squeeze of expenses.
The numbers show a clear split. Revenue from operations fell 9.8% year-on-year to ₹30.17 crore. Yet, net profit jumped 73.1% to ₹2.06 crore. This pushed the net profit margin to 6.8%, a 330 basis-point improvement from the same quarter last year.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 30.17YoY -9.8% | 22.89 | 33.45 |
| Profit (₹ Cr) | 2.06YoY +73% | 1.54 | 1.19 |
| Net Profit Margin | 6.8%YoY +94% | 6.7% | 3.5% |
The Cost-Control Engine
The profit leap was powered by a 12.2% year-on-year drop in total expenses. This sharp contraction, reported by Alfafinder, more than compensated for the softer top line. Sequentially, revenue rebounded 31.8% from a weak Q1, suggesting some demand recovery.
A nearly 97% quarter-on-quarter spike in interest cost, however, signals higher working capital usage. Employee costs also rose 46.6% year-on-year, which may reflect structural hiring for expansion.
A Strategic Pivot Underway
Management is focused on structural change, not near-term guidance. The board recently appointed two new independent directors and has proposed a fund raise via a preferential issue, according to corporate announcements.
This aligns with the company’s ongoing capital restructuring, including the acquisition of a stake in Kesar Pharma. The strategic shift aims for long-term transformation over immediate earnings momentum.
Market Reaction and Valuation Gap
The stock closed at ₹7.07 on November 13, the day before the results. It trades at a P/E of 15.3, a steep 70.7% discount to the industry average of 52.2, as per the verified analysis. This gap reflects the market’s caution toward smaller pharmaceutical traders amid sector-wide pricing scrutiny.
Key Points
- Net profit surged 73% year-on-year to ₹2.06 crore, driven by a 12.2% contraction in total expenses.
- Revenue declined 9.8% YoY but recovered 31.8% sequentially from a low Q1 base.
- The company is undergoing strategic restructuring, with a proposed fund raise and new board appointments.
- The stock trades at a significant discount to the sector P/E, reflecting its niche trading model.
Hexa Perspective
This quarter highlights a cost-led profitability model that may have limits. The sharp expense reduction provided a one-time boost, but sustaining profit growth will require revenue to catch up. The planned capital raise and board refresh suggest a focus on long-term structure. Investors are weighing this transformation against the company's reliance on trading margins in a competitive, regulated sector. The next few quarters will show if the strategic shifts can build a more durable earnings foundation.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
